Enanta Triggers MACD Death Cross, KDJ Death Cross on 15-Minute Chart.

Enanta's 15-minute chart has exhibited a critical technical signal, as the Moving Average Convergence Divergence (MACD) indicator has recently crossed below the signal line, a phenomenon known as the MACD Death Cross. Additionally, the KDJ (KST-Dynamic) indicator has also crossed below the signal line, denoted as the KDJ Death Cross. These occurrences, which transpired on August 26, 2022 at 11:00, suggest a significant downward trend in the stock price, accompanied by a shift in momentum towards the downside, potentially resulting in further decreases in the stock's value.

Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA) has recently filed a lawsuit against Pfizer Inc. (NYSE: PFE) in the European Union's Unified Patent Court (UPC), alleging patent infringement related to Pfizer's COVID-19 treatment, Paxlovid. The suit, action number 35071/2025, targets Pfizer's activities in 18 EU countries and is based on Enanta's patent application for coronavirus protease inhibitors [1].

Enanta claims that Pfizer's patent for Paxlovid is based on its own research and that infringement proceedings will take place within 12 months. If found guilty, further proceedings would be necessary to assess damages. The patent at the center of the dispute, EP 4 051 265, was granted by the European Patent Office and is the European counterpart to U.S. Patent No. 11,358,953, which is involved in ongoing U.S. litigation between Enanta and Pfizer Inc. [2].

Under UPC procedures, a hearing on the infringement action is expected to occur within the court's 12-month target timeframe, with the decision anticipated within weeks thereafter. If the UPC determines infringement occurred, subsequent proceedings would be required to determine damages. All timelines remain subject to potential appeals and other customary proceedings in European patent litigation [3].

Enanta Pharmaceuticals is dedicated to creating novel, small molecule drugs for viral infections and immunological diseases. The company's clinical programs are currently focused on respiratory syncytial virus (RSV) and its earlier-stage immunology pipeline aims to develop treatments for inflammatory diseases by targeting key drivers of the type 2 immune response, including KIT and STAT6 inhibition. Glecaprevir, a protease inhibitor discovered by Enanta, is part of one of the leading treatment regimens for curing hepatitis C virus (HCV) infection and is sold by AbbVie in numerous countries under the tradenames MAVYRET® (U.S.) and MAVIRET® (ex-U.S.) [1].

Enanta's filing of this suit is part of its ongoing efforts to protect its intellectual property in the area of small-molecule drug development. The company cautions investors not to place undue reliance on forward-looking statements, as actual outcomes and results may differ materially from what is expressed in such statements [3].

References:
[1] https://www.ainvest.com/news/enanta-sues-pfizer-covid-19-treatment-patent-infringement-europe-2508/
[2] https://www.investing.com/news/company-news/enanta-files-patent-infringement-suit-against-pfizer-over-paxlovid-93CH-4201876
[3] https://www.morningstar.com/news/business-wire/20250820282912/enanta-pharmaceuticals-files-patent-infringement-suit-against-pfizer-in-the-unified-patent-court-of-the-european-union